Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBillionToOne, Inc. Class A Common Stock

BillionToOne, Inc. Class A Common Stock

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
110.23 USD -1.77 ( 1.58%)
Last update at 2026-11-11T21:16:00Z
VOLUME
835912
Market Cap
3997.65M
P/E
621.21

Momentum Score

…

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
108.90
Low
115.44
High
52 Week Price Range
61.96
Low
138.70
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BillionToOne is a molecular diagnostics company focused on non‑invasive genetic testing, primarily developing prenatal assays that use a proprietary molecular counting platform to detect single‑gene disorders from cell‑free DNA. Long‑term growth could be supported by wider clinical adoption of single‑gene NIPT, expansion of the test menu and lab partnerships, and improvements in reimbursement and international reach. Investors may find the company attractive for its differentiated technical approach to prenatal diagnostics and potential to address an underserved clinical niche.

The most important risks are early commercial scale with execution and financing needs, regulatory and reimbursement uncertainty, and significant competition from established diagnostics firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
112.00
Dividend Yield
-
Revenue TTM
305.11M
Revenue Per Share
19.22
Gross Profit TTM
208.46M
Debt / Equity
0.23
ROE
2.30%
Net Debt
-387.08M
ROCE
2.74%
Diluted EPS TTM
0.14

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Income before tax 7.76M -41.54M -82.67M
Net income 7.45M -41.57M -82.68M
Selling general administrative 143.05M - -
Gross profit 208.46M 80.92M 17.31M
Reconciled depreciation 11.91M - -
Ebit - -39.16M -79.40M
Ebitda 16.02M -27.47M -72.94M
Depreciation and amortization - 11.69M 6.46M
Operating income 16.02M -47.15M -69.50M
Other operating expenses 289.09M 199.73M 141.22M
Interest expense 0.10M 2.39M 3.27M
Tax provision 0.30M - -
Interest income 7.75M - -
Net interest income 7.66M - -
Income tax expense 0.30M 0.03M 0.01M
Total revenue 305.11M 152.58M 71.73M
Total operating expenses 192.44M 128.06M 86.80M
Cost of revenue 96.65M 71.67M 54.42M
Total other income expense net -8.26M 5.61M -13.18M
Net income from continuing ops 7.45M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Total assets 632.65M 302.06M 191.68M
Intangible assets 0.59M 0.23M -
Other current assets 5.42M 2.90M 1.94M
Total liab 152.55M 134.31M 161.20M
Total stockholder equity 480.11M 167.75M 30.47M
Other current liab 32.99M 15.06M 6.82M
Capital stock 0.00M - -
Retained earnings -274.75M -282.20M -240.63M
Cash 495.98M 191.48M 97.27M
Total current liabilities 47.96M 28.39M 66.80M
Current deferred revenue 2.19M 2.81M 3.02M
Net debt -387.08M -82.10M 49.08M
Short term debt 5.60M 6.22M 53.74M
Short long term debt total 108.89M 109.38M 146.35M
Other stockholder equity 754.85M 30.55M 21.58M
Total current assets 560.56M 227.82M 115.50M
Net receivables 41.62M 24.71M 9.09M
Long term debt 57.23M - -
Inventory 17.55M 8.73M 7.20M
Accounts payable 7.18M 4.30M 3.21M
Non currrent assets other 4.99M 5.39M 2.31M
Non current assets total 72.10M 74.24M 76.18M
Capital lease obligations 51.67M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Investments 0.00M - -
Total cashflows from investing activities -8.92M -5.43M 82.84M
Net borrowings -1.73M - -
Total cash from financing activities 288.82M 141.02M 13.40M
Net income 2.92M -41.57M -82.68M
Change in cash 304.50M 94.21M 97.27M
Begin period cash flow 191.48M 97.27M -
End period cash flow 495.98M 191.48M 97.27M
Total cash from operating activities 24.59M -41.38M -53.67M
Issuance of capital stock 292.04M - -
Depreciation 11.91M 11.69M 6.46M
Other cashflows from investing activities - -0.03M -0.99M
Change to inventory -8.81M -1.53M -1.41M
Change to account receivables -16.91M -15.62M -2.59M
Sale purchase of stock 0.00M -0.55M -
Capital expenditures 8.88M 5.40M 6.17M
Change in working capital -22.05M -16.77M 3.79M
Stock based compensation 15.91M - -
Other non cash items 31.82M 5.27M 18.75M
Free cash flow 15.71M -46.78M -59.85M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BLLN
BillionToOne, Inc. Class A Common Stock		 -1.77
1.58%		 110.23 621.21 - 13.10 8.33 11.83 182.71
TMO
Thermo Fisher Scientific Inc		 -0.49
0.07%		 717.71 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.80
0.34%		 235.31 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.84 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.50
1.94%		 25.10 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

BillionToOne, Inc. Class A Common Stock

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

1035 O?Brien Drive, Menlo Park, CA, United States, 94025

(650) 460-2551

https://www.billiontoone.com

713

Name Title Year Born
Dr. Oguzhan Atay Ph.D. Co-Founder, Chairman & CEO 1989
Dr. David Tsao Ph.D. Co-Founder, President, CTO & Director 1990
Mr. Ross Taylor Jr., M.B.A. Chief Financial Officer 1963
Ms. Nancy Johnson Senior Vice President of Sales & Commercial Operations 1963
Ms. Jean Hayden VP of Business Operations & Chief of Staff NA
Mr. John D. Lister J.D. Chief Administrative Officer 1975
Mr. Thomas P. Lynch J.D. Chief Compliance Officer, General Counsel & Secretary 1967
Ms. Jaclyn Eng Vice President of Marketing NA
Mr. Vaghar Haghiri Senior Director of People Operations NA
Ms. Shan Riku Sakakibara M.B.A. Chief Product Officer 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…